These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 30649739)
1. Safety of Novel Targeted Therapies in Oncology. Shah RR; Curigliano G Drug Saf; 2019 Feb; 42(2):157-158. PubMed ID: 30649739 [No Abstract] [Full Text] [Related]
2. What do we mean by targeted therapy? Sledge GW Clin Breast Cancer; 2001 Oct; 2(3):169. PubMed ID: 11899412 [No Abstract] [Full Text] [Related]
3. Targeted drugs take centre stage at US cancer meeting. McCarthy M Lancet; 2001 May; 357(9268):1593. PubMed ID: 11377652 [No Abstract] [Full Text] [Related]
4. Nanoimaging devices illuminate tumor margins during surgery. Patlak M J Natl Cancer Inst; 2011 Feb; 103(3):173-4. PubMed ID: 21242334 [No Abstract] [Full Text] [Related]
5. Liposomal therapies in oncology: does one size fit all? Sousa I; Rodrigues F; Prazeres H; Lima RT; Soares P Cancer Chemother Pharmacol; 2018 Nov; 82(5):741-755. PubMed ID: 30116847 [TBL] [Abstract][Full Text] [Related]
6. Oncology and pharmacogenetics in 2007. Stebbing J Pharmacogenomics; 2007 Jan; 8(1):17-9. PubMed ID: 17187504 [TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
9. European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006. Schiavon G; Santini D; Vincenzi B; Tonini G Expert Opin Biol Ther; 2007 Feb; 7(2):269-78. PubMed ID: 17250464 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring in oncology: does it have a future? McMahon G; O'Connor R Bioanalysis; 2009 Jun; 1(3):507-11. PubMed ID: 21083145 [No Abstract] [Full Text] [Related]
12. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560 [TBL] [Abstract][Full Text] [Related]
13. Nanotechnology: Future of Oncotherapy. Gharpure KM; Wu SY; Li C; Lopez-Berestein G; Sood AK Clin Cancer Res; 2015 Jul; 21(14):3121-30. PubMed ID: 26180057 [TBL] [Abstract][Full Text] [Related]
14. Targeted and tailored therapy in hemato-oncology: vision for the 21st century. Shpilberg O; Ben-Bassat I; Raanani P Isr Med Assoc J; 2006 Dec; 8(12):843-4. PubMed ID: 17214100 [TBL] [Abstract][Full Text] [Related]
16. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Singh S; Sharma A; Robertson GP Cancer Res; 2012 Nov; 72(22):5663-8. PubMed ID: 23139207 [TBL] [Abstract][Full Text] [Related]
17. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. Elez E; Macarulla T; Tabernero J Ann Oncol; 2008 Sep; 19 Suppl 7():vii146-52. PubMed ID: 18790937 [No Abstract] [Full Text] [Related]
18. The changing landscape of phase I trials in oncology. Wong KM; Capasso A; Eckhardt SG Am Soc Clin Oncol Educ Book; 2015; ():3-8. PubMed ID: 25993134 [No Abstract] [Full Text] [Related]
19. [Advances in medical oncology]. Shi YK Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):305-10. PubMed ID: 16900620 [TBL] [Abstract][Full Text] [Related]
20. Transport Barriers and Oncophysics in Cancer Treatment. Nizzero S; Ziemys A; Ferrari M Trends Cancer; 2018 Apr; 4(4):277-280. PubMed ID: 29606312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]